FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011496> ?p ?o ?g. }

• W4377011496 endingPage "e0280209" @default.
• W4377011496 startingPage "e0280209" @default.
• W4377011496 abstract "High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with Severe Immune Reconstitution Inflammatory Syndrome (Severe-IRIS-KS), which can occur after initiating cART, and leads to high mortality, particularly in patients with pulmonary involvement. We investigate if valganciclovir (as an anti-HHV-8 agent) initiated before cART reduces the mortality associated with Severe-IRIS-KS and the incidence of Severe-IRIS-KS.Open-label parallel-group randomized clinical trial in AIDS cART naïve patients with disseminated KS (DKS) as defined by at least two of the following: pulmonary, lymph-node, or gastrointestinal involvement, lymphedema, or ≥30 skin lesions. In the experimental group (EG), patients received valganciclovir 900 mg BID four weeks before cART and continued until week 48; in the control group (CG), cART was initiated on week 0. Non-severe-IRIS-KS was defined as: an increase in the number of lesions plus a decrease of ≥one log10 HIV-VL, or an increase of ≥50cells/mm3 or ≥2-fold in baseline CD4+cells. Severe-IRIS-KS was defined as abrupt clinical worsening of KS lesions and/or fever after ruling out another infection following cART initiation, and at least three of the following: thrombocytopenia, anemia, hyponatremia, or hypoalbuminemia.40 patients were randomized and 37 completed the study. In the ITT analysis, at 48 weeks, total mortality was the same in both groups (3/20), severe-IRIS-KS attributable mortality was 0/20 in the EG, compared with 3/20 in the CG (p = 0.09), similar to the per-protocol analysis: 0/18 in the EG, and 3/19 in the control group (p = 0.09). The crude incidence rate of severe-IRIS-KS was four patients developed a total of 12 episodes of Severe-IRIS-KS in the CG and two patients developed one episode each in the EG. Mortality in patients with pulmonary KS was nil in the EG (0/5) compared with 3/4 in the CG (P = 0.048). No difference was found between groups in the number of non-S-IRIS-KS events. Among survivors at week 48, 82% achieved >80% remission.Although mortality attributable to KS was lower in the EG the difference was not statistically significant." @default.
• W4377011496 created "2023-05-19" @default.
• W4377011496 creator A5001124179 @default.
• W4377011496 creator A5029875994 @default.
• W4377011496 creator A5044903701 @default.
• W4377011496 creator A5077023411 @default.
• W4377011496 creator A5077105494 @default.
• W4377011496 creator A5077656733 @default.
• W4377011496 creator A5084024098 @default.
• W4377011496 creator A5087406609 @default.
• W4377011496 date "2023-05-17" @default.
• W4377011496 modified "2023-10-14" @default.
• W4377011496 title "Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial" @default.
• W4377011496 cites W116371937 @default.
• W4377011496 cites W160421560 @default.
• W4377011496 cites W1828428758 @default.
• W4377011496 cites W1851498616 @default.
• W4377011496 cites W1930190979 @default.
• W4377011496 cites W1969905859 @default.
• W4377011496 cites W1972740067 @default.
• W4377011496 cites W1980011486 @default.
• W4377011496 cites W1982047106 @default.
• W4377011496 cites W1982677586 @default.
• W4377011496 cites W1983636374 @default.
• W4377011496 cites W1994964684 @default.
• W4377011496 cites W2000206256 @default.
• W4377011496 cites W2017658660 @default.
• W4377011496 cites W2020311314 @default.
• W4377011496 cites W2020403066 @default.
• W4377011496 cites W2024374396 @default.
• W4377011496 cites W2024761637 @default.
• W4377011496 cites W2026453471 @default.
• W4377011496 cites W2032541700 @default.
• W4377011496 cites W2038782272 @default.
• W4377011496 cites W2048660375 @default.
• W4377011496 cites W2059067102 @default.
• W4377011496 cites W2065974405 @default.
• W4377011496 cites W2069520743 @default.
• W4377011496 cites W2085011832 @default.
• W4377011496 cites W2092575386 @default.
• W4377011496 cites W2094614562 @default.
• W4377011496 cites W2097681908 @default.
• W4377011496 cites W2104107907 @default.
• W4377011496 cites W2104264048 @default.
• W4377011496 cites W2117344292 @default.
• W4377011496 cites W2133064188 @default.
• W4377011496 cites W2136623393 @default.
• W4377011496 cites W2153248309 @default.
• W4377011496 cites W2159499388 @default.
• W4377011496 cites W2161636943 @default.
• W4377011496 cites W2163117709 @default.
• W4377011496 cites W2241007345 @default.
• W4377011496 cites W2276019048 @default.
• W4377011496 cites W2288247862 @default.
• W4377011496 cites W2319467670 @default.
• W4377011496 cites W2332308021 @default.
• W4377011496 cites W2518488421 @default.
• W4377011496 cites W2617996692 @default.
• W4377011496 cites W2627064828 @default.
• W4377011496 cites W2789343266 @default.
• W4377011496 cites W2808153222 @default.
• W4377011496 cites W2883918923 @default.
• W4377011496 cites W2916496948 @default.
• W4377011496 cites W2937257746 @default.
• W4377011496 cites W2945433359 @default.
• W4377011496 cites W3132640489 @default.
• W4377011496 cites W4254862698 @default.
• W4377011496 doi "https://doi.org/10.1371/journal.pone.0280209" @default.
• W4377011496 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37195970" @default.
• W4377011496 hasPublicationYear "2023" @default.
• W4377011496 type Work @default.
• W4377011496 citedByCount "0" @default.
• W4377011496 crossrefType "journal-article" @default.
• W4377011496 hasAuthorship W4377011496A5001124179 @default.
• W4377011496 hasAuthorship W4377011496A5029875994 @default.
• W4377011496 hasAuthorship W4377011496A5044903701 @default.
• W4377011496 hasAuthorship W4377011496A5077023411 @default.
• W4377011496 hasAuthorship W4377011496A5077105494 @default.
• W4377011496 hasAuthorship W4377011496A5077656733 @default.
• W4377011496 hasAuthorship W4377011496A5084024098 @default.
• W4377011496 hasAuthorship W4377011496A5087406609 @default.
• W4377011496 hasBestOaLocation W43770114961 @default.
• W4377011496 hasConcept C126322002 @default.
• W4377011496 hasConcept C141071460 @default.
• W4377011496 hasConcept C142462285 @default.
• W4377011496 hasConcept C168563851 @default.
• W4377011496 hasConcept C203014093 @default.
• W4377011496 hasConcept C2522874641 @default.
• W4377011496 hasConcept C2776009029 @default.
• W4377011496 hasConcept C2776317777 @default.
• W4377011496 hasConcept C2779778235 @default.
• W4377011496 hasConcept C2779820661 @default.
• W4377011496 hasConcept C2993143319 @default.
• W4377011496 hasConcept C3019738921 @default.
• W4377011496 hasConcept C71924100 @default.
• W4377011496 hasConcept C90924648 @default.
• W4377011496 hasConceptScore W4377011496C126322002 @default.
• W4377011496 hasConceptScore W4377011496C141071460 @default.

• next